Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into surviv...

Full description

Saved in:
Bibliographic Details
Published in:Journal of experimental & clinical cancer research 2019-08, Vol.38 (1), p.368-368, Article 368
Main Authors: Li, Fengzhi, Aljahdali, Ieman, Ling, Xiang
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
BIRC5
Cancer
Care and treatment
cIAP2
Drug discovery
Humans
Licensing, certification and accreditation
Mcl-1
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - pathology
Oncology, Experimental
Prognosis
Review
Survivin
Survivin - antagonists & inhibitors
Survivin cancer therapeutics
XIAP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into survivin's functional role in cancers, thus providing promise for survivin as a cancer therapeutic target. Despite this, moving survivin-targeting agents into and through the clinic remains a challenge. In order to address this challenge, we may need to rethink current strategies in order to develop a new mindset for targeting survivin. In this Review, we will first summarize the current survivin mechanistic studies, and then review the status of survivin cancer therapeutics, which is classified into five categories: (i) survivin-partner protein interaction inhibitors, (ii) survivin homodimerization inhibitors, (iii) survivin gene transcription inhibitors, (iv) survivin mRNA inhibitors and (v) survivin immunotherapy. We will then provide our opinions on cancer therapeutics using survivin as a target, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy.
ISSN:1756-9966
0392-9078
1756-9966
DOI:10.1186/s13046-019-1362-1